Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirogabalin in Patients With Herpes Zoster
NCT07307170Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Dec 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of mirogabalin in herpes zoster (HZ) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Average Numeric Rating Scale at 4 weeks. Started Dec 2025; status: recruiting.
02
Drugs
mirogabalin
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT07307170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07307170.